From fifteen years in intensive care to a decade ahead of it

Who is Dr. Erietta Galani?

Dr. Erietta Galani is an internal medicine and intensive care physician who now practises longevity medicine in Athens. She qualified at the National and Kapodistrian University of Athens, completed a dual specialty in internal medicine and intensive care, and spent fifteen years managing human physiology at its limits, first in Athens and then in university hospitals in Brussels.

Intensive care is an unusual training ground for preventive medicine, and it is precisely why she practises it. In an ICU you watch the last chapter of processes that began quietly fifteen or twenty years earlier: the coronary event that a calcium score would have predicted, the metabolic collapse that a body composition scan would have flagged, the cancer that presented late because nobody was looking.

"My background is intensive care, where disease is met at its latest stage. What interests me now is measurement and follow-up at a much earlier one."

How does she use artificial intelligence in patient care?

Her Stanford training in machine learning for clinical data informs a deliberately conservative position: models read first, physicians decide last. Software is used to surface interval change across imaging and to fuse five domains of data into one longitudinal picture. It is not used to make a diagnosis, to communicate a finding, or to write a protocol.

Patients notice the consequence rather than the method. Nothing arrives in your inbox as a raw risk score without a physician's sentence attached to it, and no flagged shadow becomes a referral before a doctor has looked at it. The reasoning behind that sequencing is described in more depth on the AI-assisted diagnostic day page.

What does she actually believe about aging?

That aging leaves measurable traces, and that those measurements can guide treatment. Not reversed in the marketing sense, and not stopped, but tracked: a pace of aging that runs slower than the calendar, a risk map redrawn before an event rather than after one, and a body composition at sixty that would have been respectable at forty-five.

She is equally clear about the limits. Some therapies carry decades of clinical evidence and some carry promising early research, and patients are told which is which before they consent to anything. Where a claim cannot be measured on a follow-up test, it is not made here. If that approach fits how you think, the scopes of assessment are laid out on the approach page.

Where to go next